Early stage venture group Ohio TechAngel Funds has raised $2.5 million for its third investment fund. Like the group's previous funds, Ohio TechAngel Fund III will invest in Ohio-based technology companies in the life and physical sciences, and information technology industries.
GeneSightRx uses either a blood test or cheek swab to check for several genetic variants that can alter the effectiveness of 24 psychiatric drugs such as Paxil, Prozac and Haldol for afflictions ranging from depression and anxiety. The analysis can, for example, suggest certain patients won't absorb drugs into the system and risk increased side effects. A physician could then adjust the dosage or prescribe something else as a result.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cleveland-based AIM Pharmakon and Cincinnati's AssureRx both this week received economic development incentives from the state of Ohio.
Innovation in medical devices. Innovation in vaccines. Even innovation in regulating drug development -- MedCity News saw it all last week.
New chief executive James S. Burns is the former head of oncology and inflammatories drugmaker EntreMed. "This is a signal to our current and next investors that we're ready to make the next step," said Al Lucas, AssureRx's vice president of sales and marketing.